Tislelizumab

Generic Name: Tislelizumab

Brand Names: Tevimbra, Tizveni

Drug Type: Biotech

CAS Number: 1858168-59-8

Unique Ingredient Identifier: 0KVO411B3N

Background: Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication: ⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Clinical Trials

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1

Withdrawn

Conditions: Refractory AML
Relapsed Adult AML

Interventions: Drug: Aza, tislelizumab

First Posted Date: 2024-09-06

Last Posted Date: 2024-09-06

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Registration Number: NCT06586099

Locations: 🇨🇳
HBDH, Tianjin, Tianjin, China

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase 1

Recruiting

Conditions: Metastatic Solid Tumors
Advanced Non-squamous Non-small-cell Lung Cancer
Advanced Colorectal Cancer
Advanced Pancreatic Ductal Adenocarcinoma
Advanced Gastric Cancer
Advanced Gastroesophageal Junction Cancer
Advanced Esophageal Adenocarcinoma

Interventions: Drug: BGB-53038
Drug: Tislelizumab
Drug: Cetuximab

First Posted Date: 2024-09-05

Last Posted Date: 2025-05-06

Lead Sponsor: BeiGene

Target Recruit Count: 177

Registration Number: NCT06585488

Locations: 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States

and more 17 locations

Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment

Phase 2

Recruiting

Conditions: Brentuximab Vedotin
Young Adult
PET Scan
Classical Hodgkin Lymphoma
Treatment
Child
Adolescent
Metabolic Response
Survival

Interventions: Drug: Brentuximab Vedotin for Injection
Radiation: response-adapted radiation
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Tislelizumab Injection
Drug: Bedamustine

First Posted Date: 2024-08-20

Last Posted Date: 2025-02-13

Lead Sponsor: Children's Cancer Group, China

Target Recruit Count: 96

Registration Number: NCT06563245

Locations: 🇨🇳
Shanghai Children's Medical Center, Shanghai, China

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Recurrent Solid Tumors

Interventions: Biological: EVM16
Drug: Tislelizumab

First Posted Date: 2024-08-07

Last Posted Date: 2025-03-18

Lead Sponsor: Peking University

Target Recruit Count: 78

Registration Number: NCT06541639

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Cancer
Metastatic Solid Tumor
Advanced Solid Tumor
Metastatic Cancer

Interventions: Drug: BGB-B3227
Drug: Tislelizumab
Drug: Chemotherapy

First Posted Date: 2024-08-06

Last Posted Date: 2025-04-13

Lead Sponsor: BeiGene

Target Recruit Count: 75

Registration Number: NCT06540066

Locations: 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States

and more 9 locations

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Phase 2

Recruiting

Conditions: Bone Metastases
Triple-negative Breast Cancer

Interventions: Drug: Tislelizumab + Nab-Paclitaxel
Other: Rankl inhibitor

First Posted Date: 2024-08-06

Last Posted Date: 2024-11-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT06538896

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Phase 2

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Etoposide
Drug: Carboplatin or Cisplatin
Radiation: Thoracic radiotherapy

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Second Hospital of Shanxi Medical University

Target Recruit Count: 40

Registration Number: NCT06536868

Locations: 🇨🇳
Jinzhong third people's hospital, Jinzhong, Shanxi, China
🇨🇳
Jincheng General Hospital, Jincheng, Shanxi, China
🇨🇳
Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

and more 3 locations

Tislelizumab in People With Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2024-07-31

Last Posted Date: 2025-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT06529523

Locations: 🇳🇬
Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇳🇬
Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria

Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Phase 3

Recruiting

Conditions: Microsatellite Instability High
Colorectal Cancer

Interventions: Drug: Tislelizumab
Drug: Adjuvant chemotherapy

First Posted Date: 2024-07-25

Last Posted Date: 2024-11-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 180

Registration Number: NCT06520683

Locations: 🇨🇳
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651, Guangzhou, Guangdong, China

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tislelizumab
Drug: Interleukin-2
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Neupogen

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 30

Registration Number: NCT06504901

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy